The principal objective of the Cemiplimab NIS with two cohorts is to examine real-world data of advCSCC patients undergoing treatment with Cemiplimab to identify potential determinants of disease progression, QoL, and other health related outcomes for advCSCC patients in a real-world setting.
The objective of this NIS is to collect and describe long-term effectiviness and safety of treatment with Cemiplimab.
Prospective and retrospective cohort: Primary objective for this Cemiplimab NIS is to evaluate the clinical outcomes in treatment of advCSCC as a result of TTNT. Assessments of the response are clinical observations of physician’s choice.